Previous work in our laboratory has provided evidence that pre-administration of apocynin and lipoic acid at subthreshold levels for neuroprotection, enhanced the neuroprotective capacity when injected in combination. Therefore, the present investigation was designed to determine if a co-drug consisting of lipoic acid and apocynin functional groups bound by a covalent bond, named UPEI-100, is capable of similar efficacy using a rodent model of stroke.
INTRODUCTION
Ischemic stroke due to occlusion of cerebral vasculature, results in hypoxia and hypoglycemia, failure of ATP-dependent pumps, disruption of ionic equilibrium and calcium homeostasis, excitotoxicity and eventual cell death (for review, see 24). Reintroduction of blood flow (ie. with thrombolytic therapy) can arrest and/or reverse these adverse events. However, if recanalization is delayed beyond 4 to 6 hours, further neuronal death, known as reperfusion injury, will occur due to the formation of reactive oxygen species (ROS; 19). Several laboratories have demonstrated that NADPH oxidase (NOX) is a major source of superoxide generation and that NOX is involved in mediating ischemia-reperfusion (I/R)-induced neuronal death (3, 9) . The pathophysiological importance of NOX in hypoxia has led many researchers to attempt to modify the activity of NOX in both permanent and transient (I/R) animal models of stroke.
Apocynin is regarded as a powerful antioxidant and anti-inflammatory agent, primarily by interfering with the assembly of the cytosolic and membrane-bound subunits to inhibit NOX activation (3, 39) . For this reason, apocynin has been tested and shown to have promise as a neuroprotectant in many rat models of stroke through its ability to attenuate ischemic damage following cerebral I/R (14, 22, 41, 42) . However, the enthusiasm over the potential clinical benefit of apocynin as a neuroprotectant has been dampened due to the narrow therapeutic doserange in which apocynin is effective (22, 40) . This is likely due to the high dose of apocynin required to measure neuroprotective effects (39) , as well as the fact that apocynin has been shown, under certain circumstances, to stimulate ROS production and thereby increase cellular oxidative stress (7) .
Lipoic acid (LA) is an antioxidant with strong free radical scavenging abilities (4) and several researchers have shown in different rat models of stroke, that administration of LA 4 produced significant neuroprotection by decreasing infarct size (15, 31, 33, 43) . Further, several laboratories have demonstrated that administration of LA in combination with another compound can produce significant neuroprotective effects exceeding the effect of either drug alone (1, 2, 18, 20) . Our laboratory has provided further support for this hypothesis and demonstrated that when using the same stroke modes as is being used in this publication, co-administration of nonprotective doses of apocynin with non-protective doses of LA produced significant neuroprotection compared to either drug injected alone (13) .
There has been recent interest in the use of co-drugs as a therapeutic approach in various pathologies (16). In several different animal models of pathology, the development and administration of a co-drug, containing LA covalently linked to another therapeutic drug, has been shown to have a greater positive effect compared to the injection of a solution containing a mixture of the two drugs (16, 38) . However, to the best of our knowledge, no research has been published examining the use of co-drug as a neuroprotectant following I/R injury. Based on our previous observation demonstrating the beneficial effects of co-administration of a solution containing apocynin with LA (13), our laboratory has developed a co-drug that is a covalent conjugate between LA and apocynin (named UPEI-100).
There is a limited window of opportunity following cerebral vascular occlusion for thrombolytic therapy to protect against further I/R-induced cell death (4 hours following the onset of clinical signs in humans). This represents a critical time frame within which to study the efficacy of neuroprotectants. Also, most cardiovascular consequences following stroke occur within the first 4-6 hrs post-stroke in humans (27). Therefore, it is our intention to examine the acute, neuroprotective effects of a co-drug, UPEI-100, using a rodent model of I/R recently developed and validated in our laboratory (12) . We examined tissue harvested from the ischemic
MATERIALS AND METHODS
All experiments were carried out in accordance with the guidelines of the Canadian Council on Animal Care and were approved by the University of Prince Edward Island Animal Care Committee.
General surgical procedures
All experiments were conducted on male Sprague-Dawley rats (total of 229 rats; 250-350 g; Charles Rivers; Montreal, PQ, CAN). For all animals, food and tap water were available ad libitum. Rats were anaesthetized with sodium thiobutabarbital (Inactin; Sigma-Aldridge;
St.Louis, MO, USA; 100 mg/kg; ip), which provided a stable plane of anesthesia for the full duration of the experimental time period. To monitor blood pressure and heart rate, a polyethylene catheter (PE-50; Clay Adams, Parsippany, NJ, USA) was inserted into the right femoral artery. For intravenous administration of drugs, a second polyethylene catheter (PE-10; Clay Adams, Parsippany, NJ, USA) was inserted into the right femoral vein. Arterial blood pressure was measured with a pressure transducer (Gould P23 ID, Cleveland, OH) connected to a Gould model 2200S polygraph. Heart rate was determined from the pulse pressure using a Gould tachograph (Biotach). These parameters were displayed and analyzed using PolyviewPro/32 data-acquisition and analysis software (Grass; Warwick, RI, USA). An endotracheal tube was inserted to facilitate breathing. Body temperature was monitored and maintained at 37 ± 1 0 C using a Physitemp feedback system (Physitemp Instruments; Clifton, NJ, USA).
Middle cerebral artery occlusions (MCAO)
We have previously published the detailed methodology for permanent (MCAO) and transient (I/R) occlusion of the middle cerebral artery (12) . Briefly, animals were placed in a David Kopf stereotaxic frame (Tujunga, CA, USA) and the right middle cerebral artery (MCA) approached through a rostra-caudal incision of the skin and frontalis muscle at the approximate level of bregma. Blood flow through the MCA was impeded by the placement of surgical suture behind the MCA at 3 designated positions along the exposed vessel. The sutures were positioned so that the middle of each suture applied pressure to the underside of the MCA and impeded blood flow as confirmed using laser Doppler flowmetry (OxyFlo, Oxford-Optronix, Oxford, UK; 12). This 3-point placement of surgical sutures produced a highly reproducible and consistent focal ischemic lesion (permanent ischemia) restricted to the prefrontal cerebral cortex. For transient, ischemia-reperfusion (I/R), the sutures were left in place for 30 mins and then removed (reperfusion) to allow blood flow to return to the area for an additional 5.5 hours (209 rats received I/R). In 12 rats, sutures were left in place for 6 hours as a model of permanent ischemia
UPEI-100 synthesis
To synthesize UPEI-100, LA and apocynin were linked via a by covalent bond between the phenol hydroxy group of apocynin and the carboxylic acid group of LA. Apocynin (0.01M) was taken in a well dried 100 mL round bottom flask followed by (0.01M) of LA, 0.01M of dimethylaminopyridine (DMAP) in 50 mL anhydrous dichloromethane (CH 2 Cl 2 ). The dicyclohexylcarbodiimide (DCC; 0.01M) was added in small quantities over a period of 45 minutes. The entire reaction was performed under nitrogen atmosphere. After stirring overnight, the pure compound was purified on a silica column chromatography after an aqueous work up.
The pure compound was characterized by proton nuclear magnetic resonance spectroscopy and mass spectrometry.
Apocynin
Lipoic Acid UPEI-100
Effect of UPEI-100 on infarct volume following both transient (I/R) and permanent MCAO
To examine the effect of UPEI-100 on I/R-induced cell death, injections of UPEI-100 (0.01, 0.05, 0.1 or 0.5 mg/kg; 1 ml/kg; iv; n= 4 per group) or vehicle (25% EtOH; 1 ml/kg; iv; n=6) were made 30 minutes prior to the onset of MCAO. The sutures were left in place for 30 minutes and removed. Reperfusion was allowed for 5.5 hours and the experiment was terminated.
To examine the effect of UPEI-100 on ischemia-induced cell death only, injections of UPEI-100 (0.1 or 1.0 mg/kg; 1 ml/kg; iv; n= 4 per group) or vehicle (25% EtOH; 1 ml/kg; iv; n=4) were made 30 minutes prior to 6 hours of permanent MCAO (sutures left in place for 6 hours). The concentration of 0.1 mg/kg represents the optimal dose of UPEI-100 as determined above and 1.0 mg/kg represents a 10-fold higher concentration of the optimal dose, as the optimal dose of 0.1 mg/kg was not effective in producing neuroprotection. The experiments were terminated at the end of the 6 hours of occlusion.
To determine if UPEI-100 was neuroprotective when administered during the 30 minute period of occlusion, injections of UPEI-100 at a dose which produced optimal neuroprotection based on the dose-response-curve described above (0.1 mg/kg; 1 ml/kg; iv; n=4) or vehicle (25% 
Effect of UPEI-100 on baseline blood pressure and heart rate
To determine the effect of UPEI-100 (0.1 mg/kg; 1 ml/kg; n=4) or vehicle (25% EtOH; 1 ml/kg; n=4) administration on baseline blood pressure and heart rate, continuous recordings of blood pressure and heart rate were taken prior to and following drug or vehicle administration.
Further recordings of the parameters were made at 15, 30, 45, 60, 90 and 120 minutes following drug administration, at which time the experiment was terminated.
Effect of UPEI-100 on cardiac baroreceptor reflex sensitivity, blood pressure and heart rate following I/R
To determine the effect of drug administration on autonomic reflex activation, the baroreceptor reflex was evoked using a bolus intravenous injection of the α-adrenergic receptor agonist, phenylephrine-hydrochloride (Sigma-Aldridge; St.Louis, MO, USA; 0.1 ml; 2.5 μg/ml; iv). The ratio of the peak change in the magnitude of the reflex bradycardia to the magnitude of the phenylephrine-induced pressor response (ΔHR/ΔMAP) was used as a measure of baroreceptor reflex sensitivity (BRS; 51). BRS was tested at 10 minutes and immediately prior to UPEI-100 (0.1 mg/kg; 1 ml/kg; n=3) or vehicle (25% EtOH; 1 ml/kg; n=3) administration. 
Time course of the effect of UPEI-100 on infarct volume following I/R
To examine the effect of UPEI-100 on the change in infarct volume over the 5.5 hours of reperfusion, injections of the optimal dose of UPEI-100 (0.1 mg/kg; 1 ml/kg; iv; n=4 per group) or vehicle (25% EtOH; 1 ml/kg; iv; n=4) were made 30 minutes prior to the onset of MCAO.
The sutures were left in place for 30 minutes. Brains were removed and infarct volume was 
Effect of UPEI-100 on markers of oxidative stress
To examine the effect of UPEI-100 on various markers of oxidative stress throughout the 5.5 hours of reperfusion, injections of the optimal dose of UPEI-100 (0.1 mg/kg; 1 ml/kg; iv; n=5 per group at each time point) or vehicle (25% EtOH; 1 ml/kg; iv; n=5 per group at each time 
Statistical analysis
Data were analyzed using a statistical software package (SigmaStat and SigmaPlot; Jandel Scientific, Tujunga, CA). All data are presented as a mean ± standard error of the mean (S.E.M). Differences were considered statistically significant if p ≤ 0.05 by an analysis of variance (ANOVA) followed by a Bonferoni post-hoc analysis. When only two groups were being compared the Student's t-test was used.
RESULTS

The effect of pre-administration of UPEI-100 on infarct volume
This experiment was designed to determine the effect of UPEI-100 pre-administration on infarct volume following I/R. Pre-administration of UPEI-100 resulted in a dose-dependent neuroprotection with a dose of 0.1 and 0.5 mg/kg resulting in a significant decrease in infarct volume compared to the administration of vehicle (p≤0.05; Fig.1A ).
To examine the effect of UPEI-100 on ischemia-induced cell death only, injections of UPEI-100 (0.1 or 1.0 mg/kg) or vehicle were made 30 minutes prior to 6 hours of MCAO (sutures left in place for 6 hours). Neither concentration of UPEI-100 (the optimal dose of 0.1 mg/kg as determined above or 1.0 mg/kg, a 10-fold increase in the optimal dose) produced significant neuroprotection when infarct volume was measured 6 hours following the start of MCAO (p≥0.05; Fig. 1B ).
The effect of systemic UPEI-100 injection on blood pressure and heart rate
The following experiment was designed to determine the effect of UPEI-I00 on arterial pressure and heart rate for a period of 2 hours following administration. Mean baseline arterial pressure and mean heart rate prior to drug administration was 112 ± 11 mm/Hg and 388 ± 26 bpm. Administration of UPEI-100 (0.1 mg/kg; i.v.) did not significantly alter mean arterial blood pressure or mean heart rate at any time point during the 2 hour continuous recording compared to vehicle (p≥0.05; data not shown).
The effect of UPEI-100 pre-administration on cardiovascular parameters following I/R
The following experiment was designed to determine the effect of pre-administration of UPEI-100 on mean arterial pressure, mean heart rate, and the mean cardiac baroreceptor reflex sensitivity (BRS) before, during and following 30 minutes of MCAO. Mean arterial pressure, heart rate and BRS prior to UPEI-100 administration were 119 ± 15 mmHg, 402 ± 22 bpm, and 0.55 ± 0.05 bpm/mmHg respectively and prior to vehicle administration were 110 ± 9 mmHg, 
The effect of intracortical injections of UPEI-100 on infarct volume following I/R
This experiment was designed to determine the effect of direct cortical pre-injection with UPEI-100 on infarct volume following I/R. UPEI-100 pre-injection resulted in a dose-dependent neuroprotection with a dose of 1.0 µM resulting in a significant decrease in infarct volume compared to the intracortical pre-injection of vehicle (p≤0.05; Fig.4 ).
Time course for the effect of UPEI-100 on infarct volume
In animals pre-treated with UPEI-100 (0.1 mg/kg) or vehicle and undergoing MCAO for 30 minutes, we observed a rapid increase in infarct volume from 30 minutes into the reperfusion period until 2 hours of reperfusion (Fig. 5) . After 2 hours of reperfusion, the mean infarct volume continued to increase significantly in the vehicle group. In contrast to the vehicle pretreated group, the mean infarct volume in the UPEI-100 group did not increase further during the remaining reperfusion period (Fig. 5 ). In addition, the mean infarct volume in the UPEI-100 group was significantly smaller than the vehicle pre-treated group when measured at 4 and 6 hours (p≤0.05 at each time point; Fig. 5 ). By the end of the 5.5 hours of reperfusion, the mean infarct volume of the UPEI-100 group was approximately 53 % smaller than the vehicle group.
Effect of UPEI-100 on SOD activity
In animals pre-treated with UPEI-100 or vehicle and undergoing MCAO for 30 minutes, we did not observe any significant differences in cytoplasmic SOD1 activity levels between these two groups at any time point during 5.5 hours of reperfusion (p≥0.05 for each time point measured; Fig. 6A ).
In contrast, mitochondrial SOD2 activity levels at the 4 hour time point were significantly higher in the UPEI-100 group compared to vehicle (p≤0.05; Fig. 6B ). There were no other significant differences measured at any time point, however, the SOD2 activity levels were consistently higher in the UPEI-100 group compared to those in the vehicle pre-treated group at each time point (Fig. 6B ).
Effect of UPEI-100 on glutathione (GSH) levels
We did not measure any significant differences in the total amount of GSH (includes both oxidized and reduced forms) in brain samples taken from either UPEI-100 or vehicle treated rats at any time point (p≥0.05 for each comparison; Fig. 6C ). In contrast, the amount of the oxidized form of GSH (GSSG) was significantly greater in the UPEI-100 treated rats than the amount of GSSG measured in vehicle treated rats after 5.5 hours of reperfusion (p≤0.05; Fig. 6D ). There was no difference in the level of GSSG between the two groups at any other time point (p≥0.05 at each time point; Fig. 6D ).
Effect of UPEI-100 on hydrogen peroxide levels
In UPEI-100 pre-treated rats, the level of hydrogen peroxide was not significantly greater than the level of hydrogen peroxide in vehicle treated rats at any time point over the 5.5 hours of reperfusion (p>0.05; Fig. 6E ). However, in both UPEI-100 and vehicle pre-treated groups, the level of hydrogen peroxide increased significantly over time (p<0.05; Fig.6E ).
Effect of UPEI-100 on protein (HNE-His) adduct levels
The following experiment was designed to determine whether UPEI-100 mediated neuroprotection resulted in a change in HNE-His adduct levels. HNE-His adduct levels following UPEI-100 administration 30 minutes prior to occlusion were significantly attenuated compared to vehicle administered following 2 hours of reperfusion (p≤0.05; Fig. 6F ). HNE-His adduct levels were not significantly different in the two groups at any other time point (p≥0.05
for each time point measured; Fig. 6F ).
Effect of UPEI-100 on DNA fragmentation (apoptotic cell death)
The following experiment was designed to determine whether the UPEI-100 mediated neuroprotection observed was mediated by an alteration in the extent of apoptotic cell death.
DNA fragmentation was quantified as an indicator of apoptotic cell death. No significant changes in the extent of DNA fragmentation in animals pre-treated with either UPEI-100 or vehicle throughout the experimental time course were observed (p≥0.05 for each time point measured; Fig. 6G ).
DISCUSSION
Oxidative stress associated with excessive production of reactive oxygen species (ROS) is a fundamental mechanism of brain damage in reperfusion injury following ischemic stroke.
The multiplicity of mechanisms involved in ischemia-and reperfusion-induced neuronal damage following an occlusive stroke remains an obstacle in providing treatment in clinical settings (26).
Drugs targeting more than one mechanism of action could potentially overcome this dilemma.
The synthesis and development of co-drugs using simple yet biologically relevant molecules as In this study, we determined that UPEI-100, a chemical combination of two naturally occurring antioxidants, LA and apocynin, produced dose-dependent neuroprotection against neuronal cell death as observed in a previously validated, novel model of ischemia-reperfusion (I/R) injury (12) . The results demonstrated that UPEI-100 produced dose-dependent, short-term neuroprotection (within 5.5 hours of reperfusion) in a model of focal ischemia which is restricted to the cerebral cortex. Further, the dose of UPEI-100 required to produce significant neuroprotection (0.1 mg/kg) was many fold less compared to the doses required for either apocynin or LA on their own (14, 15) . Also, this optimal dose of UPEI-100 produced significant neuroprotection when administered 15 minutes prior to the start of reperfusion, just prior to the induction of reperfusion, and 30, 60 and 90 minutes following the onset of reperfusion. The reason for administering UPEI-100 during the occlusion was to mimic the clinical situation where a patient would present during a stroke. This result does not indicate if UPEI-100 or an intermediate metabolite produced as a result of hepatic biotransformation was responsible for mediating the neuroprotective effect. We were able to reproduce the dose-dependent neuroprotection with direct cortical injections into the ischemic area which suggests that the parent compound UPEI-100, and not a metabolite(s), was responsible for producing the neuroprotection observed.
There have been other reports which demonstrated an attenuation of infarct volume when apocynin was administered during an occlusion of the MCA, but these benefits were lost when administration of apocynin was delayed following the onset of reperfusion (11, 14, 21, 40, 41) .
However, one laboratory demonstrated that administration of apocynin in gerbils 5 minutes following 5 minutes of global ischemia, decreased neuronal degeneration and delayed neuronal death and microglial activation when assessed 4 days later (42). It is not known if these apocynin-induced beneficial effects translated to a decrease of infarct size as it was not measured in that study. We have also demonstrated that administration of the most effective dose of LA (5 mg/kg) did not result in significant neuroprotection when administered just prior to the beginning of reperfusion, and only produced neuroprotection when administered prior to both occlusion and reperfusion (15) . It therefore appears that UPEI-100, a chemical combination of apocynin and LA is far superior then either compound alone in its ability to provide neuroprotection when administered during reperfusion. Interestingly, UPEI-100 did not produce neuroprotection when administered prior to a 6 hour permanent occlusive stroke (no reperfusion). These results support the suggestion that UPEI-100 produced neuroprotection against reperfusion injury alone, perhaps via decreasing ROS production, as ROS-induced growth of ischemic volume due to reperfusion injury has been demonstrated by many labs (23), and/or possibly via free radical scavenging.
Clinically, elevated sympathetic tone (sympathoexcitation) and abnormal electrocardiograms have been observed within 1 to 2 hours following thrombolytic or hemorrhagic stroke involving the MCA (27, 28). Such autonomic dysfunction increases the risk of sudden cardiac death (27, 28) and can be mimicked in rat models of MCAO (8).
Arrhythmogenesis and sudden cardiac death, which can occur following MCAO in humans, is associated with depressed baroreflex sensitivity (BRS; 5). Our results have demonstrated that during the 30 minute occlusion, BRS was significantly depressed and administration of UPEI-100 did not alter the level of BRS depression despite the UPEI-100-induced neuroprotection.
The increase in neuronal survival represented by an attenuated ischemic volume was not associated with recovery of autonomic function. Our laboratory has demonstrated a similar dissociation between changes in infarct volume and autonomic function following drug intervention prior to MCAO (34) . We suggest that for an agent injected systemically, it may be required to have multiple sites of action within the CNS as well as in the periphery (such as the myocardium) to decrease or reverse the sympathoexcitation and subsequent autonomic function observed following stroke. Many studies have demonstrated significant neurochemical and electrophysiological alterations in extracortical autonomic and cardiovascular regulatory nuclei shortly following MCAO (35) . This suggests that any drug which demonstrates functional cardiovascular protection may be required to act extracortically to prevent an abnormal sympathetic outflow and to restore or prevent changes in autonomic function following MCAO.
Neuronal hypoxia and the ensuing mitochondrial response are involved in both the initiation of both necrotic and apoptotic pathways leading to cell death (10) . Severe cerebral ischemia causes neuronal mitochondria to be unable to produce adenosine triphosphate leading to necrotic cell death (10) . The mitochondrial antioxidant enzyme, manganese superoxide dismutase (SOD2) is the primary cellular defense enzyme involved protecting cells from oxidative stress (10) and has been shown to reduce oxidative stress following cerebral I/R (10) as SOD2-deficient mice have enhanced infarct size following cerebral ischemia (11) and overexpression of SOD2 provided neuroprotection following cerebral ischemia (11) . We observed enhanced SOD2 activity throughout the 5.5 hours of reperfusion (reaching significance following 4 hours of reperfusion) when UPEI-100 was administered 30 minutes prior to I/R. We have previously demonstrated using the same model of I/R that LA administered 30 minutes prior to I/R also increased SOD2 activity (15) while apocynin was ineffective (14) in altering SOD2 activity. UPEI-100 did not alter cytosolic copper-zinc SOD (CuZnSOD or SOD1) activity which is consistent with previous results from our laboratory where neither of the two parent compounds, apocynin or lipoic acid, altered SOD1 activity (14, 15 ). There appears to be support in the literature for a selective effect of LA on mitochondrial function as LA is a protein bound cofactor for mitochondrial α-ketoacid dehydrogenase and serves a critical role in mitochondrial energy metabolism (37) . In addition, exogenous LA is reduced to dihydro-lipoic acid (DHLA) within the mitochondria (37) and both lipoic acid and DHLA have been shown to have powerful antioxidant activity and ROS scavenger abilities (29). Therefore, we conclude that that at least part of UPEI-100-induced neuroprotection may be due to the actions of the LA functional group of UPEI-100 on SOD2 activity.
Glutathione is another key intracellular antioxidant and protects cells by scavenging free radicals (for review, see 36) . Glutathione is involved with the breakdown of peroxides, regulating the nitric acid cycle, DNA synthesis and repair, and maintenance of protein disulfide bonds. In addition to its role in the prevention of oxidative stress, glutathione also helps maintain exogenous antioxidants such as vitamins C and E. Within cells, glutathione exists as reduced (GSH) and oxidized states (GSSG). In healthy cells, more than 90% of the total glutathione pool is in the reduced form while less than 10% exists in the oxidized or disulfide
form. An increased level of GSSG is generally indicative of enhanced oxidative stress.
Interestingly, we have reported above that UPEI-100 administration resulted in a significant increase in the amount of GSSG at the 5.5 hours of reperfusion time interval. It is possible that the UPEI-100-induced enhancement in the activity of SOD2 during the 5.5 hours of reperfusion resulted in higher levels of hydrogen peroxide production. However, the measured levels of hydrogen peroxide were not different between vehicle and UPEI-100 groups indicating that the neurons were able to adequately deal with this excess hydrogen peroxide. Hydrogen peroxide may be fully reduced to water, but may also form hydroxyl radicals in the presence of ferrous or cuprous ions (30). A slow increase in hydroxyl radical levels over the 5.5 hours of reperfusion following UPEI-100 administration could have attenuated the activity of glutathione reductase, the enzyme responsible for reducing GSSG into GSH, resulting in enhanced levels of GSSG as measured following 5.5 hours of reperfusion.
Lipid peroxidation in models of I/R occurs very quickly (6, 42) and byproducts of lipid peroxidation can form adducts with proteins and DNA and thus may play an important role in the underlying mechanism for oxidative stress-induced neuronal apoptosis (9) . Our data suggest that UPEI-100 pretreatment resulted in a decrease in I/R-induced lipid and protein peroxidation (HNE-HIS adducts) at 2 hours of reperfusion, suggesting that UPEI-100 was effective in preventing oxidative stress at this time point. Interestingly, the 2 hour time point represents the time when the infarct volume of the UPEI-100 and vehicle treated groups diverge (Fig. 5) . Since the level of apoptotic death, measured as the amount of DNA fragmentation, remained the same at all time points during reperfusion, this would suggest that the growth in infarct volume in the vehicle-treated group may have been primarily due to necrotic cell death. We speculate that the increase in neuronal survival measured when rats were pretreated with UPEI-100 was due to the ability of UPEI-100 to attenuate reperfusion-induced oxidative stress and subsequent necrotic cell death.
We therefore conclude that during the initial period following stroke and reperfusion, UPEI-100-induced neuroprotection was primarily due to increased SOD2 activity, thereby causing an increase in the neurons ability to immediately deal with reperfusion-induced mitochondrial superoxide production. This, along with reduced peroxidation of lipids and proteins as a result of oxidative stress, combined to produce our observed neuroprotective capacity of UPEI-100. We should mention that although we conducted time-dependent measures of molecular mediators of cellular stress pathways, these changes do not necessarily suggest a cause-and-effect relationship between UPEI-100 and these proteins. This is particularly true since the temporal changes in these proteins do not correspond to all time points in which neuroprotection was observed. Therefore, studies are currently underway utilizing siRNA technology to establish this relationship.
Perspectives and Significance
At present, there are no pharmacological treatments available other than thrombolytic therapy such as tissue plasminogen activator (t-PA), and this is used in only about 4% of patients presenting to a hospital following an acute ischemic stroke (25). In addition, patients must present themselves to a hospital within approximately 4 hours of the stroke onset to be eligible for tPA therapy (19). Providing effective pharmacological treatment immediately following an acute stroke to lessen the cerebral damage remains an elusive goal. UPEI-100 is a potential therapeutic candidate to protect against the negative outcomes associated with reperfusioninduced ischemia.
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